SCHEMBL13880959

SCHEMBL13880959

O=C(CCN1C(=O)C=CC1=O)Nc1ccc(CCC(=O)N2CCC2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
MEN1 O00255 2/20 0.40
TSHR P16473 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 5/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MCHR1 Q99705 2/20 0.39
CHRM1 P11229 1/20 0.39
HTR2A P28223 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13880962 0.91 ALDH1A1 (0.44) POLBKMT2AMAPTSMN1; SMN2HPGD
SCHEMBL4397929 0.89 POLB (0.40) POLBMEN1KMT2AMAPTNPC1
SCHEMBL4400652 0.88 OPRK1 (0.46) POLBMEN1TSHRKMT2AMAPT
SCHEMBL4401002 0.88 OPRK1 (0.46) POLBMEN1TSHRKMT2AMAPT
SCHEMBL23615473 0.83 HDAC3 (0.58) POLBMEN1KMT2AMAPTNPC1
SCHEMBL13625388 0.83 POLB (0.51) POLBMEN1KMT2AMAPTNPC1
SCHEMBL14297018 0.82 POLB (0.67) POLBMAPTNPC1SMN1; SMN2HSD17B10
SCHEMBL14147999 0.79 HDAC1 (0.45) POLBMEN1TSHRKMT2AMAPT
SCHEMBL14297019 0.79 POLB (0.49) POLBMEN1TSHRKMT2AMAPT
SCHEMBL13471900 0.79 ALDH1A1 (0.36) POLBMAPTSMN1; SMN2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 US disclosed
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS GLP1R, GIPR, GCGR POLB 4831/4885MEN1 1723/4885TSHR 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.